CoChat

Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment

Open access
Gmeiner, William H. · 2024 · Cancers

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index; 15 of the 101 sources its claims cite were checked for support.

Abstract

Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality worldwide. CRC mortality results almost exclusively from metastatic disease (mCRC) for which systemic chemotherapy is often a preferred therapeutic option. Biomarker-based stratification of mCRC enables the use of precision therapy based on individual tumor mutational profiles. Activating mutations in the RAS/RAF/MAPK pathway downstream of EGFR signaling have, until recently, limited the use of EGFR-targeted therapies for mCRC; however, the development of anti-RAS and anti-RAF therapies together with improved strategies to limit compensatory signaling pathways is resulting in improved survival rates in several highly lethal mCRC sub-types (e.g., BRAF-mutant). The use of fluoropyrimidine (FP)-based chemotherapy regimens to treat mCRC continues to evolve contributing to improved long-term survival. Future advances in chemotherapy for mCRC will need to position development relative to the advances made in precision oncology.

Overview

CoChat Summary

TL;DR

This review summarizes recent advances in treating colorectal cancer (CRC), emphasizing biomarker-based stratification and targeted therapies for metastatic CRC (mCRC). It highlights progress in anti-EGFR, anti-RAS, anti-BRAF, anti-VEGF, fluoropyrimidine chemotherapy, and immunotherapy, while noting that mCRC survival remains poor.

Key findings

  • CRC causes >930,000 deaths/year worldwide, with >1.9 million new diagnoses annually; by 2040, projections are >3.2 million new cases and >1.6 million deaths. mCRC 5-year survival remains <11%, though median overall survival now exceeds 32 months, improved from 22.6 months in 2012.
  • RAS/RAF/MAPK mutations limit EGFR-targeted therapy: KRAS mutations occur in ~40% of mCRC, NRAS in 3–5%, and BRAF in ~8.5%, with BRAFV600E comprising two-thirds of BRAF mutations. BRAFV600E mCRC has median survival of 13.5 months vs. 30.6 months for BRAF wild-type tumors.
  • KRASG12C occurs in <4% of mCRC; sotorasib produced objective responses in approximately 10% of patients, and adagrasib showed similar results. In BRAFV600E mCRC, encorafenib plus cetuximab increased objective response rate to 19.5% vs. 1.8% for control, and adding binimetinib increased it to 26.8%.
  • Fluoropyrimidine doublets remain central: adding oxaliplatin to 5-FU/LV increased response rate (50.7% vs. 22.3%) and progression-free survival (9.0 vs. 6.2 months), while adding irinotecan improved response rate (49% vs. 31%) and overall survival (17.4 vs. 14.1 months). Immunotherapy is approved for dMMR/MSI-high mCRC, which is <5% of mCRC cases, with some estimates that only 2% of mCRC patients are candidates for successful immune checkpoint blockade.

Methods

  • Design: narrative review of therapeutic strategies for CRC, with emphasis on mCRC.
  • Data/sample: published literature and clinical trial results; no primary patient cohort or new experimental data are reported.
  • Main analysis: narrative synthesis of biomarker-based stratification, targeted therapy development, chemotherapy regimens, and immunotherapy approaches.

Limitations

  • Stated: reported survival improvements are often based on clinical trials involving a small percentage of patients, often with favorable performance characteristics; 5-year mCRC survival remains dismal.
  • Evident from text: as a narrative review, it does not describe a systematic search strategy, formal quality assessment, or meta-analysis, and it presents no primary data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers16051029

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Biomarker-based stratification for front-line treatment of mCRC. ESMO and NCCN guidelines recommend MSI/MSS testing and comprehensive RAS and BRAF mutation status. Most mCRC is MSS (~95%) and treated with a combination of chemotherapy and targeted therapy. MSI (~5%) is treated with immune checkpoint blockade (ICB) immunotherapy. About 40% of mCRC expresses a mutant RAS protein (KRAS or NRAS), and front-line treatment frequently consists of either FOLFOX or FOLFIRI chemotherapy in combination with anti-VEGF therapy (e.g., bevacizumab). Inhibitors for specific RAS mutations (e.g., sotorasib and adagrasib for KRASG12C) are in clinical development. About 5% of mCRC expresses BRAFV600E, and recently, the combination of encorafenib+anti-EGFR (cetuximab) was FDA-approved for front-line treatment. HER2 is amplified in ~5% of mCRC, and a preferred front-line treatment is trastuzumab+lapatinib. For RASWT mCRC without BRAF mutation or HER2 amplification, chemotherapy combined with anti-EGFR therapy (cetuximab or panitumumab) is recommended front-line treatment. Acquired resistance to anti-EGFR therapy can result from ALK-fusion or NTRK-fusion with the indicated treatment.
Figure 1 Biomarker-based stratification for front-line treatment of mCRC. ESMO and NCCN guidelines recommend MSI/MSS testing and comprehensive RAS and BRAF mutation status. Most mCRC is MSS (~95%) and treated with a combination of chemotherapy and targeted therapy. MSI (~5%) is treated with immune checkpoint blockade (ICB) immunotherapy. About 40% of mCRC expresses a mutant RAS protein (KRAS or NRAS), and front-line treatment frequently consists of either FOLFOX or FOLFIRI chemotherapy in combination with anti-VEGF therapy (e.g., bevacizumab). Inhibitors for specific RAS mutations (e.g., sotorasib and adagrasib for KRASG12C) are in clinical development. About 5% of mCRC expresses BRAFV600E, and recently, the combination of encorafenib+anti-EGFR (cetuximab) was FDA-approved for front-line treatment. HER2 is amplified in ~5% of mCRC, and a preferred front-line treatment is trastuzumab+lapatinib. For RASWT mCRC without BRAF mutation or HER2 amplification, chemotherapy combined with anti-EGFR therapy (cetuximab or panitumumab) is recommended front-line treatment. Acquired resistance to anti-EGFR therapy can result from ALK-fusion or NTRK-fusion with the indicated treatment.CC BY · PubMed Central
Figure 2 Therapeutic targeting of mCRC. EGFR-family signaling initiates proliferative signaling in mCRC via the RAS/RAF/MAPK cascade. Monoclonal antibodies targeting EGFR dimer and specific heterodimers have activity in mCRC without mutations in a RAS protein or BRAF. Small molecule inhibitors of specific KRAS mutant forms and BRAFV600E have activity in mCRC. Fluoropyrimidine-based chemotherapy targets thymidylate synthase (TS) and DNA topoisomerase 1 (Top1) and causes DNA damage and replication stress.
Figure 2 Therapeutic targeting of mCRC. EGFR-family signaling initiates proliferative signaling in mCRC via the RAS/RAF/MAPK cascade. Monoclonal antibodies targeting EGFR dimer and specific heterodimers have activity in mCRC without mutations in a RAS protein or BRAF. Small molecule inhibitors of specific KRAS mutant forms and BRAFV600E have activity in mCRC. Fluoropyrimidine-based chemotherapy targets thymidylate synthase (TS) and DNA topoisomerase 1 (Top1) and causes DNA damage and replication stress.CC BY · PubMed Central
Figure 3 Sequential administration of FP-based chemotherapy for the treatment of mCRC that is RASMT and microsatellite-stable (MSS) following disease progression. Front-line treatment consists of either FOLFOX or FOLFIRI, which may be combined with anti-VEGF therapy. Second-line treatment generally uses the alternative FP-based regimen (e.g., FOLFOX → FOLFIRI) and may be combined with an alternative anti-VEGF agent (e.g., Aflibercept). Third-line treatment uses an alternative FP-based treatment, TAS-102, in which FP trifluridine is combined with Tiperacil. Regorafenib is also widely used in third-line treatment of mCRC.
Figure 3 Sequential administration of FP-based chemotherapy for the treatment of mCRC that is RASMT and microsatellite-stable (MSS) following disease progression. Front-line treatment consists of either FOLFOX or FOLFIRI, which may be combined with anti-VEGF therapy. Second-line treatment generally uses the alternative FP-based regimen (e.g., FOLFOX → FOLFIRI) and may be combined with an alternative anti-VEGF agent (e.g., Aflibercept). Third-line treatment uses an alternative FP-based treatment, TAS-102, in which FP trifluridine is combined with Tiperacil. Regorafenib is also widely used in third-line treatment of mCRC.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 4 Not valid · 69 Not checked · 19 Own results and interpretations

43 more claims · 2 with their cited sources checked

Create a free account to see all 105 claims and to verify the 86 references still open.

See all claims — free account
  • It may state two separate claims as one. 52
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 150 references

Cited by

See all 86

Metadata

Authors
Gmeiner, W. H.
Affiliations
Wake Forest University Health Sciences (US)
Corresponding author
Gmeiner, William H.
Venue
Cancers
Publisher
MDPI AG
Published
2024-03-02
Volume
16
Issue
5
Pages
1029
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4392375125
Cited by
78
References
150
Citations by year
2026: 27 · 2025: 37 · 2024: 14
FWCI
4.17
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • NIH-NCI (R42 CA254843-02A1, P30 CA 012197, CA200460)
  • Department of Defense Peer Reviewed Cancer Research Program (R42 CA254843-02A1, P30 CA 012197, CA200460)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
colorectal cancer, metastatic colorectal cancer, anti-EGFR therapy, RAS/MAPK pathway, BRAF mutation, compensatory signaling, fluoropyrimidine chemotherapy, precision oncology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. https://app.cochat.ai/papers/10.3390/cancers16051029
The paper
Gmeiner, W. H. (2024). Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. Cancers. https://doi.org/10.3390/cancers16051029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.